Schrodinger Inc. (SDGR)
NASDAQ: SDGRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
SDGR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.04B
- EPS (TTM)
- -$0.74
- Dividend yield
- None
- 52-week range
- 10.95 – 33.78
- Day range
- 26.87 – 28.43
- Volume / Avg
- 4.56M / 1.69M
- Beta
- —
- Shares outstanding
- 65.64M
- Next earnings
- Nov 4, 2026
52-week range
SDGR stock today
On Oct 7, SDGR ended the session at $27.29, shedding $1.61 (5.57%), versus the S&P 500's 0.22% decline. Volume was 2.7x the average at 4.56M shares, a sign of unusually heavy trading. At this level, SDGR sits in the middle of its 52-week range of $10.95 to $33.78: 19.2% below the high, set on Oct 6, 2026 and 149.3% above the low.
SDGR is up 52.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 35.4%. Schrodinger has posted a net loss over the last twelve months (EPS of -$0.74), so its P/E ratio is not meaningful. Schrodinger's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Schrodinger
Company profileSchrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Ramy Farid Ph.D.
- Headquarters
- New York, NY
- Employees
- 850
- IPO year
- 2020
- Website
- schrodinger.com
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$21.43-21.47%
- Strong buy 0
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.65
SDGR news
All SDGR newsSchrodinger peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VERAVera Therapeutics Inc. Class A | 30.25 | +2.82% | $2.18B | vs SDGR |
| AUPHAurinia Pharmaceuticals Inc | 16.01 | +2.04% | $2.13B | vs SDGR |
| PHVSPharvaris N.V. | 31.68 | +1.80% | $2.22B | vs SDGR |
| VRDNViridian Therapeutics Inc. | 18.28 | +0.33% | $2.07B | vs SDGR |
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs SDGR |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs SDGR |
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs SDGR |
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs SDGR |
Indexes, lists and sector
Schrodinger stock FAQ
What is Schrodinger's stock price today?
SDGR last traded at $27.29 as of Oct 7, 4:00 PM EDT, down 5.57% on the day. Prices are delayed at least 15 minutes.
When is Schrodinger's next earnings date?
Schrodinger is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.65.
Who is Schrodinger's CEO?
Dr. Ramy Farid Ph.D. is the chief executive officer of Schrodinger Inc., which has about 850 employees.
What is the SDGR 52-week high?
The 52-week high for SDGR is $33.78 and the 52-week low is $10.95. The stock is currently 19.2% below its high.